Contract development and manufacturing organisation (CDMO) firm Shanghai ZhenGe Biotechnology Co., Ltd has secured as much as $70 million in its Series B round of financing jointly led by China’s global VC Qiming Venture Partners and return backer IDG Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
